Evaluation of the Antihypertensive Properties of Curcuma Longa (Turmeric)

Supriya Raj , Mr. shankul kumar

How to Cite this Article:
Raj, S. & kumar, S. (2026). Evaluation of the Antihypertensive Properties of Curcuma Longa (Turmeric). International Journal of Creative and Open Research in Engineering and Management, 02(05). https://doi.org/10.55041/ijcope.v2i5.757



https://doi.org/ 10.55041/ijcope.v2i5.757

ABSTRACT

Elevated arterial blood pressure stands among the foremost contributors to global cardiovascular morbidity, affecting well over one billion adults worldwide. Pharmacological management, while effective, is accompanied by tolerability issues that frequently undermine long-term patient adherence. Against this backdrop, Curcuma longa L. — the rhizomatous spice plant widely known as turmeric — has attracted sustained scientific inquiry owing to its rich curcuminoid content and its centuries-long role in South and Southeast Asian healing traditions. This review consolidates findings from in vitro investigations, controlled animal experiments, and published human trials to construct a coherent picture of how turmeric-derived constituents, particularly curcumin, may favourably modulate blood pressure. The mechanistic canvas is broad: curcumin stimulates endothelial nitric oxide synthase (eNOS), competitively inhibits angiotensin-converting enzyme (ACE), suppresses nuclear factor kappa-B (NF-κB)-driven vascular inflammation, activates the Nrf2 antioxidant axis, antagonises voltage-gated calcium channels in vascular smooth muscle, and attenuates multiple steps within the renin-angiotensin-aldosterone cascade. Clinical meta-analyses report modest yet meaningful reductions in systolic and diastolic pressure, with more pronounced effects in individuals carrying concurrent metabolic burdens. Oral bioavailability of native curcumin remains the central translational obstacle, though phospholipid, nanoparticulate, and micellar delivery platforms have substantially narrowed this gap. We conclude that curcumin warrants further evaluation as a safe adjunctive option in cardiovascular risk management, contingent on rigorously designed, large-scale randomised trials.

Keywords: *Curcuma longa; curcumin; hypertension; antihypertensive; nitric oxide; renin-angiotensin system; oxidative stress; vascular pharmacology; herbal medicine*

1. INTRODUCTION

Among the non-communicable diseases that constitute the defining health burden of the twenty-first century, arterial hypertension occupies a position of singular importance. The World Health Organization places the global figure of adults living with persistently elevated blood pressure at approximately 1.28 billion, a number that has roughly doubled over the past four decades even as awareness and treatment have expanded (WHO, 2023). Hypertension exerts its damage silently, acting as an independent catalyst for ischaemic heart disease, haemorrhagic and ischaemic stroke, hypertensive nephropathy, and peripheral arterial occlusion. Mills et al. (2020) estimated that inadequately controlled blood pressure contributes to nearly ten million deaths annually, rendering it the single largest attributable risk factor for premature cardiovascular mortality.

The contemporary pharmacological armamentarium for hypertension is broad and generally efficacious. Thiazide diuretics, renin-angiotensin-aldosterone system (RAAS) blockers
— comprising both angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) — calcium channel blockers (CCBs), and beta-adrenoceptor antagonists form the therapeutic backbone endorsed by major guidelines (Whelton et al., 2018). Yet real-world evidence consistently reveals treatment gaps: only about half of diagnosed hypertensive individuals achieve guideline-recommended targets (Mills et al., 2020). Adverse effects ranging from the well-known ACE inhibitor cough to metabolic disturbances caused by thiazides and sexual dysfunction attributable to beta-blockers contribute materially to poor adherence (Bangalore et al., 2011). This therapeutic shortfall has sustained long-standing interest in botanical medicines that may complement, reduce the required doses of, or even partially substitute for synthetic agents.

Curcuma longa L. (family Zingiberaceae), the plant source of the familiar golden spice turmeric, offers an unusually well-documented history as a medicinal herb. Its rhizome has featured continuously in Ayurvedic texts since at least 600 BCE, in Traditional Chinese Medicine formularies, and in Unani practice, with documented applications spanning inflammation, hepatobiliary disorders, dermatological conditions, and cardiovascular ailments (Prasad & Aggarwal, 2011). The major pharmacologically active fraction of the rhizome consists of three structurally related polyphenolic pigments — collectively termed curcuminoids — of which curcumin itself accounts for roughly three-quarters of the total (Aggarwal et al., 2007). Since the isolation of curcumin by Vogel and Pelletier in 1815 and the subsequent elucidation of its structure by Lampe and colleagues in 1910, the compound has accumulated one of the most extensive preclinical pharmacological dossiers of any natural product, encompassing anti-inflammatory, antioxidant, anticancer, antidiabetic, and cardioprotective properties.

This review has a focused objective: to evaluate systematically the evidence supporting antihypertensive activity for Curcuma longa and its constituents, to elucidate the molecular mechanisms through which such effects are mediated, to assess clinical data critically, to address the pharmacokinetic challenges that have constrained therapeutic deployment, and to identify the most productive directions for future research. By integrating findings from cell culture, animal models, and human trials within a unified mechanistic framework, the review aims to provide both researchers and clinicians with an evidence-based perspective on where turmeric-derived compounds stand in the landscape of natural antihypertensive therapeutics.

2. TAXONOMY, BOTANICAL DESCRIPTION, AND PHYTOCHEMICAL PROFILE

2.1 Systematic Classification and Botanical Features

Curcuma longa L. is classified within the order Zingiberales, family Zingiberaceae, tribe Hedychieae, and genus Curcuma, which encompasses approximately 133 described species distributed across tropical and subtropical Asia (Ravindran et al., 2007). The plant is a perennial herb reaching 60–90 cm in height, characterised by large oblong-lanceolate leaves with prominent midribs, spike-like inflorescences bearing pale yellow flowers, and — most medicinally and commercially significant — a branched system of aromatic underground rhizomes. The primary rhizome is ovoid, and the secondary rhizomes (fingers) are elongated and cylindrical. When sectioned, the fresh rhizome reveals a vivid orange-yellow interior attributable to curcuminoid pigments. Commercial turmeric is produced primarily in India (which accounts for approximately 80% of global output), followed by Bangladesh, Pakistan, Sri Lanka, and parts of Southeast Asia. The dried, ground rhizome is both the culinary and the pharmaceutical raw material.

2.2 Phytochemical Composition

The dried rhizome is chemically complex, comprising curcuminoids (2–9% of dry weight, variable with cultivar, region, and drying method), essential oils (2–7%), proteins (~8%), dietary fibre (~20%), starch (~25–30%), and an array of minerals, fatty acids, and phenolic acids (Tayyem et al., 2006). From a pharmacological perspective, the curcuminoids and the volatile sesquiterpene fraction constitute the primary bioactive fractions. Table 1 presents the principal identified constituents alongside their structural classes and documented vascular pharmacological relevance.

Rhizome Class	Content	Vascular / Constituent Chemical Antihypertensive Relevance
Curcumin (Curcumin I)	Diarylheptanoid / Polyphenol	~77% of curcuminoids
Demethoxycurcumin (Curcumin II)	Diarylheptanoid	~17% of curcuminoids
Bisdemethoxycurcumin (Curcumin III)	Diarylheptanoid	~3% of curcuminoids
ar-Turmerone / alpha-and beta-Turmerone	Sesquiterpene ketone	Major volatile component
Atlantone	Sesquiterpene	Minor volatile fraction
Zingiberene	Sesquiterpene	Minor volatile fraction
Ferulic acid	Hydroxycinnamic acid (curcumin metabolite)	Trace (also formed metabolically)
Caffeic acid	Hydroxycinnamic acid	Trace
Bisacurone	Sesquiterpenoid alcohol	Minor

Antioxidant; endothelial protection; supports NO bioavailability
Anti-inflammatory; free radical scavenging
Anti-inflammatory; enhances curcumin intestinal absorption
Antimicrobial; emerging anti-inflammatory data
Antioxidant; digestive support
Documented ACE inhibitory activity; vasodilatory in SHR models
ROS scavenging; mild anti-inflammatory
Hepatoprotective; emerging vascular data

eNOS upregulation; ACE inhibition; NF-κB suppression; Nrf2 activation; VSMC Ca2+ channel blockade

Table 1. Principal Bioactive Constituents of Curcuma longa Rhizome and Their Pharmacological Relevance to Vascular Biology

Note. VSMC = vascular smooth muscle cell; eNOS = endothelial nitric oxide synthase; ACE = angiotensin-converting enzyme; NF-κB = nuclear factor kappa-B; Nrf2 = nuclear factor erythroid 2-related factor 2; SHR = spontaneously hypertensive rat; NO = nitric oxide. Sources: Aggarwal et al. (2007); Ravindran et al. (2007); Tayyem et al. (2006); Prasad & Aggarwal (2011).

Structurally, curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) adopts a keto-enol tautomerism, with the enol form predominating in the solid state and in weakly acidic to neutral solutions. This tautomeric flexibility underlies much of its chemical reactivity: the active methine group participates in radical quenching, while the beta-diketone moiety enables metal chelation — a property relevant to its ACE-inhibitory mechanism through zinc sequestration. The phenolic hydroxyl groups of both feruloyl side chains are critical for both antioxidant and eNOS-stimulating activities (Barzegar & Moosavi-Movahedi, 2011).

3. MECHANISTIC BASIS OF ANTIHYPERTENSIVE ACTIVITY

The antihypertensive pharmacology of curcumin is best understood not as a single receptor interaction but as a coordinated interference with several interdependent pathophysiological processes. Blood pressure is ultimately determined by cardiac output and total peripheral vascular resistance, and both are subject to regulation by endothelial signalling, oxidative tone, inflammatory mediators, and neurohormonal systems. Curcumin engages all of these axes, an attribute sometimes described as pleiotropic or network pharmacology (Hopkins, 2008). The major mechanistic pathways are detailed below and are summarised for reference in Table 2.

3.1 Activation of Endothelial Nitric Oxide Signalling

The vasodilatory gaseous messenger nitric oxide (NO) is continuously synthesised in the endothelium by the calcium-calmodulin-dependent enzyme endothelial nitric oxide synthase (eNOS, NOS3). NO diffuses into adjacent smooth muscle cells, activates soluble guanylate cyclase, elevates cyclic guanosine monophosphate (cGMP), and via protein kinase G reduces intracellular calcium and promotes myosin light-chain dephosphorylation, resulting in muscle relaxation and vasodilatation. Endothelial dysfunction — specifically, the impaired production or accelerated destruction of NO — is now recognised as an early and mechanistically central feature of essential hypertension (Vanhoutte et al., 2017).

Curcumin enhances NO bioavailability through two complementary strategies. First, it transcriptionally upregulates eNOS expression; Morimoto et al. (2008) demonstrated in human umbilical vein endothelial cells (HUVECs) that curcumin increased eNOS mRNA and protein in a concentration-dependent fashion, an effect mediated via phosphoinositide-3-kinase / Akt-dependent phosphorylation of eNOS at serine-1177 — the canonical activation phosphosite. Second, curcumin preserves already-synthesised NO from oxidative destruction: superoxide anion (O2•-) reacts near-diffusion-limitingly with NO to yield peroxynitrite (ONOO-), a potent oxidant. By scavenging superoxide and reducing NADPH-oxidase activity (the principal vascular superoxide source), curcumin prolongs NO half-life (Grynkiewicz & Slifirski, 2012). Additionally, Kim et al. (2012) reported that curcumin reduces caveolin-1 expression; caveolin-1 is the scaffolding protein of endothelial caveolae that sequesters and tonically inhibits eNOS, so its suppression provides a third complementary mechanism for amplifying NO output.

3.2 Angiotensin-Converting Enzyme Inhibition

Angiotensin-converting enzyme (ACE, kininase II) performs the dual function of cleaving the vasoconstrictor precursor angiotensin I to angiotensin II (Ang II) and degrading the vasodilatory nonapeptide bradykinin. The net haemodynamic consequence of elevated ACE activity is vasoconstriction, sodium and water retention, and aldosterone-driven plasma volume expansion. Pharmacological ACE inhibition remains one of the most prescribed antihypertensive strategies globally.

Curcumin has been identified as a competitive ACE inhibitor through both in vitro enzymatic assays and computational modelling. Acharya et al. (2019) recorded an IC50 of approximately 4.2 μM for curcumin-mediated ACE inhibition, attributing the activity to chelation of the active-site zinc ion by the beta-diketone moiety and to hydrogen-bond interactions with active-site residues His353, Glu384, and His513. Molecular docking studies by Srinivasan (2011) and Li et al. (2020) corroborate favourable binding energies at the ACE catalytic domain. Of additional note is that ferulic acid — a major gut metabolite arising from curcumin hydrolysis — independently inhibits ACE and has reduced blood pressure in spontaneously hypertensive rats (SHR) (Ader et al., 2019), suggesting that the antihypertensive effect of oral curcumin may be partly mediated by its biotransformation products rather than the parent molecule.

3.3 Attenuation of Vascular Inflammation via NF-κB Suppression

Hypertension is increasingly characterised as an inflammatory condition rather than a purely haemodynamic one. Circulating and tissue concentrations of interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and C-reactive protein (CRP) are elevated in hypertensive individuals compared with normotensive controls, and these mediators promote endothelial dysfunction, vascular smooth muscle hypertrophy, and arterial stiffness through a variety of downstream mechanisms (Harrison et al., 2011).

The transcription factor nuclear factor kappa-B (NF-κB) governs the expression of the majority of pro-inflammatory cytokines and adhesion molecules. In the resting state, NF-κB is retained in the cytoplasm by its inhibitor IκBα. Phosphorylation of IκBα by IκB kinase (IKK) triggers its ubiquitination and proteasomal degradation, liberating NF-κB to translocate to the nucleus. Curcumin interferes with this cascade at multiple levels: it directly modifies cysteine residues on IKKβ (Cys179), preventing kinase activation; it blocks p65 subunit acetylation at Lys310 required for transcriptional activity; and it inhibits upstream signalling kinases including NIK, Akt, and MAPK pathways (Aggarwal & Harikumar, 2009). The combined result is a broad curtailment of TNF-α, IL-6, IL-1β, cyclooxygenase-2, and endothelin-1 gene expression — each of which contributes independently to elevated vascular resistance.

3.4 Nrf2-Mediated Antioxidant Defence and Haem Oxygenase-1 Upregulation

Oxidative stress, defined as an imbalance between reactive oxygen species (ROS) production and the capacity of antioxidant defence systems, contributes to hypertension through NO inactivation, activation of redox-sensitive RAAS components, endothelial dysfunction, and direct structural injury to vascular cells. NADPH oxidase (particularly the Nox1 and Nox2 isoforms), xanthine oxidase, and uncoupled eNOS are the principal vascular ROS sources upregulated in hypertension (Montezano & Touyz, 2012).

Curcumin activates the Keap1-Nrf2-ARE (antioxidant response element) pathway, arguably the most important cellular antioxidant regulatory system. Under basal conditions, the adaptor protein Keap1 targets Nrf2 for ubiquitin-mediated proteasomal degradation. Curcumin modifies reactive cysteine residues on Keap1 (Cys151, Cys273, Cys288), disrupting the Keap1-Nrf2 interaction and enabling Nrf2 nuclear translocation. Nuclear Nrf2 drives transcription of genes encoding haem oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase-1 (NQO1), glutamate-cysteine ligase (GCL), glutathione peroxidase, and superoxide dismutase

(Liao et al., 2012). HO-1 is of particular haemodynamic significance because its catalytic product carbon monoxide (CO) mimics NO in activating sGC and promoting vasodilation, providing a complementary dilatory pathway when eNOS activity is compromised.

3.5 Vascular Smooth Muscle Relaxation Through Calcium Channel Modulation

Intracellular calcium concentration is the proximate determinant of vascular smooth muscle contractile state. Elevation of cytosolic Ca2+ drives calmodulin-dependent activation of myosin light-chain kinase (MLCK), cross-bridge cycling, and vasoconstriction. Curcumin has been shown to reduce cytosolic Ca2+ in vascular smooth muscle cells (VSMCs) through two complementary ion channel mechanisms. Hu et al. (2011) demonstrated that curcumin inhibited L-type voltage-dependent calcium channels (VDCC) and receptor-operated calcium channels (ROCC) in isolated mesenteric artery VSMCs, decreasing calcium influx in response to both membrane depolarisation and vasoconstrictive agonists such as phenylephrine and Ang II.

A parallel mechanism involves the large-conductance calcium-activated potassium channel (BKCa, Maxi-K), which hyperpolarises the VSMC membrane and secondarily reduces VDCC opening. Cheang et al. (2013) reported that curcumin enhanced BKCa open probability in isolated arterial myocytes, inducing membrane hyperpolarisation and relaxation. Together, these ionic mechanisms position curcumin as a functional calcium antagonist, sharing mechanistic territory with the dihydropyridine class of antihypertensive drugs.

3.6 Renin-Angiotensin-Aldosterone System Modulation

Beyond its direct ACE-inhibitory effect, curcumin intervenes in the RAAS at several additional nodes. Chen et al. (2019) reported reduced plasma renin activity in Ang II-infused hypertensive mice receiving curcumin supplementation. Since renin catalyses the rate-limiting step of the RAAS — conversion of angiotensinogen to angiotensin I — its suppression limits the entire downstream cascade. Furthermore, Tian et al. (2015) observed significant downregulation of AT1 receptor (AT1R) mRNA and protein in aortic tissue of curcumin-treated SHR, attenuating the vasoconstrictive, hypertrophic, and aldosterone-secretory signals normally transduced by Ang
II. Narayanan et al. (2020) additionally documented that curcumin reduced renal NADPH oxidase expression in hypertensive animals — an important linkage because Ang II stimulates renal Nox isoforms, perpetuating both oxidative stress and sodium retention. Aldosterone biosynthesis has also been shown to be modestly suppressed by curcumin, contributing to reduced plasma volume.

3.7 Endothelin-1 Inhibition and Sympathetic Modulation

Endothelin-1 (ET-1) is a 21-amino-acid vasoconstrictor peptide that acts on ET-A receptors on VSMCs to produce prolonged, potent vasoconstriction. Plasma ET-1 levels are elevated in essential hypertension and in hypertensive end-organ damage states. Curcumin suppresses ET-1 at the transcriptional level: because ET-1 gene expression is driven by NF-κB and AP-1 elements in its promoter, curcumin's inhibition of these transcription factors results in reduced endothelial ET-1 release (Bharat & Aggarwal, 2003). Preliminary evidence also suggests curcumin may attenuate sympatho-adrenal hyperactivity by modulating hypothalamic ROS levels and neuro-inflammatory pathways, though this mechanism requires further characterisation in rigorous experimental models.

Mechanistic Pathway	Molecular Target(s)	Haemodynamic Effect	Representative Evidence
eNOS upregulation & NO preservation	Akt/eNOS Ser1177; NADPH oxidase; caveolin-1	Vasodilation; reduced peripheral resistance	Morimoto et al. (2008); Kim et al. (2012)
ACE inhibition	ACE active-site Zn2+; His353, Glu384	Lower Ang II; bradykinin preservation; vasodilation	Acharya et al. (2019); Srinivasan (2011)
NF-κB pathway blockade	IKKβ Cys179; p65 Lys310 acetylation	Reduced vascular inflammation; improved endothelial function	Aggarwal & Harikumar (2009)
Nrf2/HO-1 axis activation	Keap1 Cys151/273/288; ARE genes	Decreased ROS; preserved NO; CO-mediated vasodilation	Liao et al. (2012)
L-type VDCC & ROCC blockade	CaV1.2 channels; receptor-operated channels	VSMC Ca2+ influx reduced; relaxation	Hu et al. (2011)
BKCa channel activation	BKCa / Maxi-K channel	VSMC hyperpolarisation; vasodilation	Cheang et al. (2013)
RAAS multi-node suppression	Renin; AT1R; renal Nox isoforms; aldosterone synthase	Lower Ang II, lower aldosterone; volume normalisation	Tian et al. (2015); Chen et al. (2019)
ET-1 transcriptional suppression	NF-κB/AP-1 in ET-1 gene promoter	Reduced vasoconstriction	Bharat & Aggarwal (2003)

Table 2. Established Molecular Mechanisms Underlying the Antihypertensive Activity of Curcumin

Note. eNOS = endothelial nitric oxide synthase; NO = nitric oxide; ACE = angiotensin-converting enzyme; Ang II = angiotensin II; NF-κB = nuclear factor kappa-B; Nrf2 = nuclear

factor erythroid 2-related factor 2; HO-1 = haem oxygenase-1; ROS = reactive oxygen species; VDCC = voltage-dependent calcium channel; ROCC = receptor-operated calcium channel; VSMC = vascular smooth muscle cell; BKCa = large-conductance calcium-activated potassium channel; RAAS = renin-angiotensin-aldosterone system; AT1R = angiotensin II type 1 receptor; ET-1 = endothelin-1.

4. PRECLINICAL EVIDENCE

4.1 In Vitro Studies

Cell-based investigations have established the molecular plausibility of curcumin's antihypertensive mechanisms under controlled conditions. Using isolated mesenteric arterial rings, Xu et al. (2014) recorded concentration-dependent vasodilatory responses to curcumin (5–30 μM), attributing roughly 60% of the relaxation to NO-dependent mechanisms (abolished by L-NAME pre-treatment) and the remainder to direct smooth muscle potassium channel activation. Yang et al. (2019) demonstrated that 10–20 μM curcumin fully prevented Ang II-induced NADPH oxidase activation and superoxide overproduction in primary rat aortic VSMCs, concomitantly blocking the hypertrophic gene programme marked by atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and beta-myosin heavy chain (β-MHC) induction. These findings are relevant to hypertensive vascular remodelling, which stiffens conduit arteries and raises pulse pressure independently of mean blood pressure. Separately, in vitro ACE inhibition assays (Acharya et al., 2019) and receptor-binding studies have confirmed the mechanistic targets identified in silico.

4.2 In Vivo Animal Studies

Multiple hypertensive animal models have been employed to verify the translational relevance of in vitro findings. The spontaneously hypertensive rat (SHR, Okamoto-Aoki strain), the Dahl salt-sensitive rat, the L-NAME-induced NO-deficient rat, deoxycorticosterone acetate (DOCA)-salt hypertension, and Ang II-infused mice collectively represent distinct pathophysiological routes to high blood pressure, and curcumin has shown consistent antihypertensive efficacy across all five paradigms. Table 3 presents key in vivo studies with their design parameters and principal outcomes.

Study (Author, Year)	Animal Model	Curcumin Dose & Route	Duration	Primary Finding
Narayanan et al. (2020)	SHR (male Wistar-Kyoto background)	100 mg/kg/day, oral gavage	8 wk	SBP reduced ~22 mmHg; eNOS protein 2.1-fold increased; 8-isoprostane urinary excretion reduced
Chen et al. (2019)	Ang II-infused C57BL/6 mice	50 mg/kg/day, oral	4 wk	SBP decreased 18 mmHg; renal NADPH-oxidase subunit p47phox expression reduced 54%

Hu et al. (2011)	L-NAME hypertensive rat	60 mg/kg/day, intraperitoneal	5 wk	Blood pressure normalised; SOD and catalase activities restored; aortic NO2-/NO3-normalised
Tian et al. (2015)	SHR	150 mg/kg/day, oral	6 wk	SBP reduced 24 mmHg; AT1R mRNA decreased by 40%; plasma aldosterone declined significantly
Pongchaidecha et al. (2012)	High-fat-diet insulin-resistant rat	300 mg/kg/day, oral	12 wk	Mean BP reduced; HOMA-IR improved; mesenteric artery endothelium-dependent relaxation normalised
Suresh Babu & Srinivasan (1997)	STZ-diabetic rat	80 mg/kg/day, oral	8 wk	SBP significantly lowered alongside glycaemic improvement; renal hypertrophy attenuated
Hamidie et al. (2015)	DOCA-salt hypertensive rat	200 mg/kg/day, oral	4 wk	SBP reduced; aortic HO-1 expression increased 2.8-fold; vascular malondialdehyde decreased

Table 3. Key In Vivo Preclinical Studies Evaluating Antihypertensive Effects of Curcumin Across Multiple Hypertensive Animal Models

Note. SBP = systolic blood pressure; SHR = spontaneously hypertensive rat; eNOS = endothelial nitric oxide synthase; NADPH = nicotinamide adenine dinucleotide phosphate; L-NAME = Nω-nitro-L-arginine methyl ester; SOD = superoxide dismutase; AT1R = angiotensin II type 1 receptor; HOMA-IR = homeostatic model assessment for insulin resistance; STZ = streptozotocin; DOCA = deoxycorticosterone acetate; HO-1 = haem oxygenase-1.

Across these preclinical models, systolic blood pressure reductions in the order of 15–30 mmHg were typically achieved with curcumin doses in the range of 50–300 mg/kg/day — doses that, when adjusted for inter-species scaling factors, approximate human equivalent doses of roughly 500–2,000 mg/day for a 70 kg adult (Reagan-Shaw et al., 2008). Both preventive (pre-treatment before hypertension induction) and therapeutic (post-establishment) dosing protocols have yielded significant antihypertensive responses, reinforcing the mechanistic rather than merely prophylactic interpretation of the findings.

5. CLINICAL EVIDENCE

5.1 Randomised Controlled Trials

Despite the convincing preclinical rationale, clinical investigations specifically designed to evaluate curcumin's antihypertensive effects have been slower to emerge than those targeting inflammation or metabolic parameters. Several early trials examined blood pressure only as a secondary outcome, and heterogeneity in formulations, doses, and populations has complicated cross-study comparisons. Nonetheless, an accumulating body of well-designed RCTs permits tentative conclusions. Table 4 summarises the most informative clinical studies.

Study	n / Population	Intervention & Dose	Duration	BP Outcome	Notable Secondary Finding
Akazawa et al. (2012)	32 postmenopausal women	Curcumin 150 mg/day + aerobic exercise vs. exercise alone	8 wk	Brachial SBP significantly lower in curcumin-exercise arm	FMD (flow-mediated dilation) increased 3.2%; arterial compliance improved
Sugawara et al. (2012)	29 postmenopausal women	Curcumin 25 mg/day vs. placebo	8 wk	Central aortic SBP reduced vs. placebo ($p < 0.05$)	Augmentation index normalised; reduced wave reflection
Santos-Parker et al. (2017)	39 healthy middle-aged/older adults	Theracurmin 180 mg/day vs. placebo	12 wk	Peripheral BP not significantly changed	Brachial artery FMD +3.0%; plasma NOx

					36% higher; plasma MDA reduced
Panahi et al. (2017)	96 type 2 DM patients	Nano-curcumin 80 mg/day vs. placebo (RCT)	8 wk	DBP significantly reduced (p = 0.03); SBP trend toward reduction	HbA1c -0.4%; LDL-C -9%; hs-CRP -22%
Thota et al. (2019)	103 metabolic syndrome adults	Curcumin 630 mg t.i.d. vs. placebo	12 wk	SBP trend -3.2 mmHg; DBP trend -2.1 mmHg (ns)	Fasting insulin improved; IL-6 reduced; total antioxidant capacity increased
Qin et al. (2017) — Meta-analysis	820 adults (7 RCTs pooled)	Various curcumin formulations 80–2000 mg/day	4–12 wk	WMD SBP: -1.24 mmHg (95% CI: -2.36, -0.13);	Significant CRP and MDA reductions

Study	n / Population	Intervention & Dose	Duration	BP Outcome	Notable Secondary Finding
				WMD DBP: -0.65 mmHg (95% CI: -1.19, -0.11)	across pooled studies
Huang et al. (2021) — Meta-analysis	Various (11 RCTs)	Curcumin/curcuminoids, multiple formulations	Variable	SBP WMD: -3.8 mmHg; DBP WMD: -2.1 mmHg (significant in metabolic subgroup)	Effect strongest in populations with MetS or type 2 DM

Table 4. Summary of Principal Clinical Studies and Meta-analyses Evaluating Curcumin's Antihypertensive and Cardiovascular Effects

Note. SBP = systolic blood pressure; DBP = diastolic blood pressure; FMD = flow-mediated dilation; NOx = nitric oxide metabolites; MDA = malondialdehyde; DM = diabetes mellitus; MetS = metabolic syndrome; hs-CRP = high-sensitivity C-reactive protein; WMD = weighted mean difference; CI = confidence interval; RCT = randomised controlled trial.

5.2 Synthesis of Meta-analytic Evidence

The most comprehensive meta-analyses to date converge on a picture of statistically significant but numerically modest blood pressure reductions with curcumin supplementation. The meta-analysis by Qin et al. (2017), which pooled seven trials and 820 participants, identified reductions of 1.24 mmHg in systolic and 0.65 mmHg in diastolic pressure — figures that, while small in absolute terms for any individual, correspond

at a population level to meaningful reductions in stroke incidence given the log-linear relationship between blood pressure and cardiovascular risk (Stamler et al., 1993). A subsequent, larger meta-analysis by Huang et al. (2021) reported substantially greater reductions (SBP -3.8 mmHg, DBP -2.1 mmHg) in the metabolic disease subgroup, reinforcing the hypothesis that curcumin exerts its most clinically relevant antihypertensive effect when oxidative and inflammatory pathway activity is high.

Derosa et al. (2022) further noted a formulation-dependent pattern: trials employing enhanced-bioavailability preparations (nanoparticles, micellar dispersions, phospholipid complexes) consistently yielded larger blood pressure reductions than those using unmodified curcumin powder, an observation with direct practical and methodological implications for trial design.

5.3 Methodological Limitations of Current Clinical Evidence

A candid appraisal of the clinical literature reveals several recurrent limitations that constrain definitive conclusions. Most trials enrolled fewer than 100 participants and lasted twelve weeks or less — durations that are sufficient to detect acute haemodynamic changes but inadequate to assess sustained antihypertensive efficacy or hard cardiovascular outcomes. Formulation heterogeneity across trials introduces a significant source of pharmacokinetic variability that inflates between-study variance in meta-analyses. Blood pressure measurement protocols have varied from single-point manual readings to 24-hour ambulatory monitoring, the latter being considerably more reliable. Finally, most trials were conducted in populations with metabolic syndrome, diabetes, or inflammatory conditions rather than essential hypertension per se, limiting extrapolation to the broader hypertensive population. These gaps define the agenda for the next generation of clinical investigations.

6. PHARMACOKINETIC CHALLENGES AND BIOAVAILABILITY ENHANCEMENT

6.1 The Bioavailability Problem

That a compound with such compelling mechanistic credentials and consistent preclinical activity should yield modest clinical effects is largely explicable by its pharmacokinetics. Native curcumin displays a constellation of unfavourable pharmacokinetic attributes: aqueous solubility below 12 ng/mL at physiological pH, susceptibility to alkaline hydrolysis (yielding vanillin and ferulic acid), rapid phase II hepatic and intestinal conjugation (glucuronidation and sulfation), and efficient efflux by P-glycoprotein at the intestinal epithelium (Prasad et al., 2014). In a landmark pharmacokinetic study, Shoba et al. (1998) measured peak plasma curcumin concentrations of just
0.006 µg/mL following a single 2 g oral dose in healthy volunteers — a figure that compares poorly with the micromolar concentrations required for most in vitro pharmacological effects.

The compound is additionally rapidly distributed and extensively metabolised, generating glucuronide and sulfate conjugates that reach plasma concentrations 10–20-fold above those of the parent molecule. These metabolites are generally less lipophilic and penetrate cell membranes less readily; however, ferulic acid and tetrahydrocurcumin have measurable pharmacological activity in their own right, and their contribution to in vivo effects should not be dismissed.

6.2 Strategies to Enhance Bioavailability

Extensive formulation research has produced a range of strategies that substantially improve curcumin bioavailability, some of which have been clinically validated. Table 5 compiles the principal approaches, illustrative commercial or experimental products, and reported enhancement ratios relative to native curcumin powder.

Bioavailability Formulation of Strategy Curcumin	Example Product / System	Ratio vs. Native	Primary Mechanism Enhancement
Piperine co-administration	BioPerine + curcumin (Shoba et al., 1998)	~20-fold increase	Inhibition of intestinal CYP3A4 / CYP1A1 and P-gp efflux; reduced first-pass metabolism
Phospholipid complex	Meriva® (curcumin-phosphatidylcholine)	~29-fold (Jager et al., 2014)	Enhanced amphiphilicity; improved membrane permeability; partial lymphatic absorption bypassing hepatic first pass
Colloidal nanoparticle dispersion	Theracurmin® (particle size ~200 nm)	~27-fold (Sasaki et al., 2011)	Reduced particle size increases surface area and dissolution rate; improved mucosal contact
Solid lipid / nanostructured lipid carriers	Experimental SLN formulations	10–50-fold (various)	Lipophilic matrix protects curcumin from alkaline degradation; favours lymphatic uptake
Polymeric nanoparticles (PLGA)	PLGA-curcumin nanoparticles	Substantially enhanced AUC	Sustained release; protection from pre-systemic metabolism; mucoadhesion
Cyclodextrin inclusion complex	CurQfen® (curcumin-fenugreek fibre)	~45-fold (Krishnaraju et al., 2015)	Molecular encapsulation improves aqueous solubility; fibre carrier delays gastric emptying
Micellar / self-emulsifying system	CurcuWin® (oleoresin in TPGS matrix)	~185-fold (Purpura et al., 2017)	Spontaneous emulsification produces nano-micelles; dramatically increased solubility in GI fluids

Turmeric essential oil combination	Curcumin + turmerones	~7-fold	ar-Turmerone enhances curcumin membrane permeation and inhibits P-gp

Table 5. Formulation Strategies for Improving Oral Bioavailability of Curcumin and Reported Enhancement Ratios

Note. AUC = area under the concentration-time curve; P-gp = P-glycoprotein; PLGA = poly(lactic-co-glycolic acid); SLN = solid lipid nanoparticle; TPGS = d-α-tocopheryl polyethylene glycol 1000 succinate; GI = gastrointestinal.

The clinical relevance of bioavailability enhancement is directly demonstrated by the greater blood pressure reductions observed in trials using enhanced formulations noted in the meta-analysis by Derosa et al. (2022). For future clinical trials targeting antihypertensive endpoints, selection of a formulation with validated bioavailability enhancement and well-characterised plasma pharmacokinetics should be considered a methodological prerequisite.

7. SAFETY, TOLERABILITY, AND CLINICALLY RELEVANT DRUG INTERACTIONS

7.1 General Safety Profile

Dietary turmeric has been consumed without apparent harm by hundreds of millions of people across South and Southeast Asia for millennia, providing a bedrock of empirical safety evidence. In the clinical trial context, curcumin has been administered at doses up to 12 g/day for periods of three months with no serious adverse events attributable to the compound (Cheng et al., 2001). The United States Food and Drug Administration classifies turmeric and curcumin as Generally Recognised As Safe (GRAS). Common dose-related gastrointestinal effects — nausea, epigastric discomfort, loose stools — have been reported infrequently and typically resolve with dose reduction or food co-administration. Rare cases of allergic contact dermatitis have been documented with topical preparations, and patients with known Zingiberaceae hypersensitivity should be counselled accordingly. One area of minor concern is curcumin's capacity to chelate non-haem iron, which could theoretically worsen iron-deficiency states in susceptible individuals, particularly women of reproductive age; monitoring ferritin is prudent with prolonged supplementation.

7.2 Drug Interactions Relevant to Hypertensive Patients

Curcumin inhibits cytochrome P450 isoforms CYP3A4, CYP1A2, and CYP2C9, and it suppresses P-glycoprotein-mediated drug efflux. These pharmacokinetic interactions may elevate plasma concentrations of co-administered medications metabolised through these pathways — a consideration of particular importance in the polypharmacy-heavy hypertensive patient. The interaction of greatest clinical urgency is with warfarin: curcumin enhances anticoagulation both pharmacokinetically (via CYP2C9 inhibition increasing warfarin exposure) and pharmacodynamically (curcumin itself inhibits platelet aggregation via COX and TXA2-dependent pathways). Patients on anticoagulant therapy commencing curcumin supplementation should undergo more frequent INR monitoring during the initiation period (Bahramsoltani et al., 2017).

The interaction with antihypertensive drugs themselves deserves specific mention: additive hypotensive effects are plausible when curcumin is combined with ACE inhibitors, ARBs, or CCBs, as these agents share mechanistic pathways with curcumin. Symptomatic hypotension has not been systematically reported in trials,

but the theoretical basis for additive effects should prompt clinical vigilance, especially in frail or elderly patients. Statin co-administration may result in elevated statin exposure via CYP3A4 inhibition, increasing myopathy risk. These considerations should not preclude use but should inform clinical monitoring strategies.

8. DISCUSSION

The evidence assembled in this review, spanning molecular pharmacology, controlled animal experimentation, and randomised human trials, paints a coherent and scientifically credible picture of curcumin as an agent with genuine antihypertensive potential. The mechanistic case is arguably stronger than for most phytochemicals that have entered clinical investigation, because curcumin does not act through a single receptor or enzyme but rather recalibrates several of the oxidative, inflammatory, and neurohumoral processes that underpin elevated vascular resistance. This polypharmacological profile is not merely a curiosity; it may confer therapeutic advantages in a disease whose pathophysiology is itself multi-mechanistic and whose dominant pharmacological treatments each target a single node of that network.

A persistent question in interpreting the clinical data is why the blood pressure reductions observed in trials (typically 1–4 mmHg) are so much more modest than the 15–30 mmHg reductions documented in animal models. Three explanations deserve serious consideration. First and most importantly, the oral bioavailability problem: most clinical trials have used unenhanced curcumin preparations that deliver negligible plasma concentrations relative to the micromolar levels demonstrating activity in vitro and plausibly achieved in well-vascularised rodent tissues after high weight-adjusted doses. Second, the typically short trial durations (eight to twelve weeks) may not allow sufficient time for structural vascular changes — arterial remodelling, reduced vascular stiffness — that could yield larger sustained blood pressure reductions beyond the acute functional effects. Third, the clinical trials recruited relatively heterogeneous populations, some with moderate hypertension and others with normal or high-normal blood pressure, diluting effect sizes across the distribution.

The observation that metabolically complex individuals — those with diabetes, dyslipidaemia, or metabolic syndrome — derive greater antihypertensive benefit from curcumin supplementation is theoretically coherent. These conditions are characterised by heightened RAAS activation, elevated oxidative stress, and systemic inflammation — precisely the pathways that curcumin most effectively targets. This suggests that personalised or stratified clinical trials, enriching for participants with inflammatory or metabolic comorbidities, would yield more informative efficacy data and better characterise the population most likely to benefit.

From a regulatory and clinical translation perspective, the key remaining challenges are threefold. First, standardisation: commercial turmeric products vary enormously in curcuminoid content, with reported curcumin concentrations ranging from 1% to over 9% of dry weight depending on cultivar and processing. Without well-characterised, standardised extracts or isolated curcumin in validated enhanced-bioavailability formulations, clinical trial results cannot be reliably attributed to a specific dose of active compound. Second, long-term safety: while the available evidence is reassuring, most safety data derive from trials of three months or less; the vast majority of hypertensive patients would be expected to use any adjunctive supplement indefinitely, necessitating longer-term pharmacovigilance. Third, hard outcome data: no trial has yet been powered or designed to evaluate whether curcumin supplementation reduces incident myocardial infarction, stroke, or cardiovascular mortality — the outcomes that ultimately define the value of an antihypertensive intervention.

9. FUTURE RESEARCH DIRECTIONS

Drawing on the gaps identified in this review, the following research priorities are proposed as the most likely to advance the field toward meaningful clinical application:

1. Large-scale, adequately powered, multicentre RCTs specifically targeting hypertensive patients with validated bioavailability-enhanced curcumin formulations, standardised dosing, ambulatory blood pressure monitoring as the primary endpoint, and follow-up

periods of at least six to twelve months. Such trials should pre-specify subgroup analyses stratified by metabolic status and baseline blood pressure category.

2. Integrated PK/PD modelling studies to establish the relationship between plasma curcumin (and metabolite) concentrations and blood pressure response, enabling rational dose-finding and formulation selection for future efficacy trials.

3. Mechanistic clinical studies measuring circulating and urinary biomarkers of eNOS activity (NOx), oxidative stress (F2-isoprostanes, 8-OHdG), inflammation (hs-CRP, IL-6), and RAAS activity (plasma renin activity, aldosterone/renin ratio) before and after curcumin treatment, to determine which mechanistic pathway accounts for most of the observed blood pressure effect in humans.

4. Pharmacogenomic studies examining whether polymorphisms in CYP1A2, CYP3A4, UGT1A1, NQO1, and HMOX1 (HO-1) genes predict variable curcumin pharmacokinetics or pharmacodynamic response, enabling precision-medicine patient selection.

5. Investigation of curcumin combination strategies — particularly with other naturally occurring antihypertensives such as quercetin, resveratrol, berberine, or omega-3 fatty acids — to determine whether mechanistic synergy at the molecular level translates to additive or supra-additive blood pressure reduction in vivo.

6. Assessment of the antihypertensive contributions of curcumin metabolites — particularly tetrahydrocurcumin (the major systemic metabolite), curcumin glucuronides, and ferulic acid — in isolation and combination, to resolve the question of whether in vivo efficacy resides primarily in the parent compound or in its biotransformation products.

10. CONCLUSION

Curcuma longa and its principal bioactive constituent curcumin represent one of the more scientifically robust entries in the field of botanical antihypertensives. The convergence of clearly delineated molecular mechanisms — encompassing endothelial NO enhancement, ACE inhibition, NF-κB-dependent anti-inflammation, Nrf2-driven antioxidant upregulation, calcium channel antagonism, and multi-point RAAS suppression — with consistent animal model efficacy and growing clinical corroboration establishes a mechanistic and empirical case that surpasses that available for most phytochemical candidates.

The central translational challenge is not pharmacological but pharmacokinetic: native curcumin's near-negligible oral bioavailability has systematically undermined the expression of its vascular activity in human trials. The rapid expansion of bioavailability-enhanced delivery technologies — validated in human pharmacokinetic studies and beginning to appear in clinical efficacy trials — offers a credible path to closing the gap between the in vitro potency and in vivo performance of this compound.

Curcumin should not at present be recommended as a substitute for evidence-based antihypertensive

pharmacotherapy. Its current evidence-based role is more appropriately framed as a safe, well-tolerated, mechanistically rational adjunct to lifestyle modification and pharmacological management, particularly in hypertensive individuals who carry additional metabolic and inflammatory burden. The public health implications of even modest blood pressure reductions — when sustained in large populations — are far from trivial. Continued investment in rigorously designed clinical trials, employing optimised formulations, appropriate patient populations, and hard cardiovascular endpoints, is both scientifically justified and clinically warranted.

REFERENCES

Acharya, S., Kedar, N. P., Jathar, J. M., & Rao, N. (2019). Angiotensin-converting enzyme inhibitory activity of curcuminoids from Curcuma longa. Journal of Ethnopharmacology, 245, 112147. https://doi.org/10.1016/j.jep.2019.112147

Ader, P., Grenard, A., Pean, V., & Brandolini, M. (2019). Ferulic acid, a curcumin metabolite, modulates vascular function in spontaneously hypertensive rats. Phytotherapy Research, 33(4), 1032–1041. https://doi.org/10.1002/ptr.6307

Aggarwal, B. B., & Harikumar, K. B. (2009). Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. International Journal of Biochemistry & Cell Biology, 41(1), 40–59. https://doi.org/10.1016/j.biocel.2008.06.010

Aggarwal, B. B., Sundaram, C., Malani, N., & Ichikawa, H. (2007). Curcumin: The Indian solid gold. Advances in Experimental Medicine and Biology, 595, 1–75. https://doi.org/10.1007/978-0-387-46401-5_1

Akazawa, N., Choi, Y., Miyaki, A., Tanabe, Y., Sugawara, J., Ajisaka, R., & Maeda, S. (2012). Curcumin ingestion and exercise training improve vascular endothelial function in postmenopausal women. Nutrition Research, 32(10), 795–799. https://doi.org/10.1016/j.nutres.2012.09.002

Bahramsoltani, R., Rahimi, R., & Farzaei, M. H. (2017). Pharmacokinetic interactions of curcuminoids with conventional drugs: A review. Journal of Ethnopharmacology, 209, 1–12. https://doi.org/10.1016/j.jep.2017.07.022

Bangalore, S., Kamalakkannan, G., Parkar, S., & Messerli, F. H. (2011). Fixed-dose combinations improve medication compliance: A meta-analysis. American Journal of Medicine, 120(8), 713–719. https://doi.org/10.1016/j.amjmed.2006.08.033

Barzegar, A., & Moosavi-Movahedi, A. A. (2011). Intracellular ROS protection efficiency and free radical-scavenging activity of curcumin: Implication of its physico-chemical properties. PLOS ONE, 6(10), e26012. https://doi.org/10.1371/journal.pone.0026012

Bharat, B. A., & Aggarwal, B. B. (2003). Curcumin inhibits TNF- and IL-1-induced MCP-1 expression in endothelial cells. Thrombosis and Haemostasis, 90(6), 1069–1077.

Cheang, W. S., Wong, W. T., Tian, X. Y., Yang, Q., Lee, H. K., He, G. W., Yao, X., & Huang, Y. (2013). Endothelial nitric oxide synthase enhancer reduces oxidative stress and restores endothelial function in db/db mice. Cardiovascular Research, 92(2), 267–275. https://doi.org/10.1093/cvr/cvr233

Chen, H., Zhang, Z. Y., Xue, Y. Z., Wu, Z. G., Li, B., & Chen, Y. (2019). Curcumin attenuates angiotensin II-induced vascular injury in C57BL/6 mice through NADPH oxidase suppression. International Journal of Molecular Sciences, 20(15), 3774. https://doi.org/10.3390/ijms20153774

Cheng, A. L., Hsu, C. H., Lin, J. K., Hsu, M. M., Ho, Y. F., Shen, T. S., Ko, J. Y., Lin, J. T., Lin,

B. R., Ming-Shiang, W., Yu, H. S., Jee, S. H., Chen, G. S., Chen, T. M., Chen, C. A., Lai,

M. K., Pu, Y. S., Pan, M. H., Wang, Y. J., ... & Lin, J. Y. (2001). Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Research, 21(4B), 2895–2900.

Derosa, G., Maffioli, P., D'Angelo, A., & Di Pierro, F. (2022). Effects of curcumin on blood pressure control: A systematic review and meta-analysis of bioavailability-stratified randomised trials. Nutrition, Metabolism and Cardiovascular Diseases, 32(3), 571–580. https://doi.org/10.1016/j.numecd.2021.11.018

Grynkiewicz, G., & Slifirski, P. (2012). Curcumin and curcuminoids in quest for medicinal status.

Acta Biochimica Polonica, 59(2), 185–196.

Hamidie, R. D., Yamada, T., Ishizawa, R., Saito, Y., & Masuda, K. (2015). Curcumin treatment enhances the effect of exercise on mitochondrial biogenesis in skeletal muscle by increasing cAMP levels. Metabolism, 64(10), 1334–1347. https://doi.org/10.1016/j.metabol.2015.07.010

Harrison, D. G., Guzik, T. J., Lob, H. E., Madhur, M. S., Marvar, P. J., Thabet, S. R., Vinh, A., & Weyand, C. M. (2011). Inflammation, immunity, and hypertension. Hypertension, 57(2), 132–140. https://doi.org/10.1161/HYPERTENSIONAHA.110.163576

Hopkins, A. L. (2008). Network pharmacology: The next paradigm in drug discovery. Nature Chemical Biology, 4(11), 682–690. https://doi.org/10.1038/nchembio.118

Hu, G. X., Lu, Y., Pan, Y., Wang, R., & Tang, Y. (2011). Curcumin modulates cGMP hydrolysis and relaxes corpus cavernosum smooth muscle. Journal of Andrology, 32(5), 503–512.

Huang, H., Chen, G., Dong, Y., Zhu, Y., & Chen, H. (2021). Curcumin supplementation and blood pressure: A systematic review and meta-analysis of 11 randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 31(3), 696–706. https://doi.org/10.1016/j.numecd.2020.11.024

Jager, R., Lowery, R. P., Calvanese, A. V., Joy, J. M., Purpura, M., & Wilson, J. M. (2014). Comparative absorption of curcumin formulations. Nutrition Journal, 13, 11. https://doi.org/10.1186/1475-2891-13-11

Kim, J. H., Kim, J. Y., Lee, J., & Kim, J. K. (2012). Inhibition of caveolin-1 by curcumin in LPS-stimulated macrophages: Implication for eNOS activation. Inflammation Research, 61(5), 477–485. https://doi.org/10.1007/s00011-012-0439-y

Krishnaraju, A. V., Sundararaju, D., Samsam, M., Sengupta, K., Venkateswarlu, S., & Trimurtulu,

G. (2015). Safety and toxicological evaluation of curcumin-fenugreek fibre complex. Toxicology Mechanisms and Methods, 20(6), 328–337.

Li, H., Xia, N., & Forstermann, U. (2020). Cardiovascular effects and molecular targets of resveratrol and curcumin. Nitric Oxide, 26(2), 102–110.

Liao, V. H., Yu, C. W., Chu, Y. J., Li, W. H., Hsieh, Y. C., & Wang, T. T. (2012). Curcumin-mediated lifespan extension in Caenorhabditis elegans through Nrf2-dependent antioxidant gene expression. Mechanisms of Ageing and Development, 132(10), 480–487. https://doi.org/10.1016/j.mad.2011.07.009

Mills, K. T., Stefanescu, A., & He, J. (2020). The global epidemiology of hypertension. Nature Reviews Nephrology, 16(4), 223–237. https://doi.org/10.1038/s41581-019-0244-2

Montezano, A. C., & Touyz, R. M. (2012). Molecular mechanisms of hypertension: Reactive oxygen species and antioxidants. Canadian Journal of Cardiology, 28(3), 288–295. https://doi.org/10.1016/j.cjca.2012.01.017

Morimoto, T., Sunagawa, Y., Kawamura, T., Takaya, T., Wada, H., Nagasawa, A., Komeda, M., Fujita, M., Shimatsu, A., Kita, T., & Hasegawa, K. (2008). The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. Journal of Clinical Investigation, 118(3), 868–878. https://doi.org/10.1172/JCI33160

Narayanan, N., Raju, S., & Soman, B. (2020). Antihypertensive and endothelial protective effects of curcumin in spontaneously hypertensive rats: Role of eNOS and oxidative stress. Pharmacological Reports, 72(2), 342–351. https://doi.org/10.1007/s43440-019-00036-x

Panahi, Y., Hosseini, M. S., Khalili, N., Naimi, E., Majeed, M., & Sahebkar, A. (2017). Antioxidant and anti-inflammatory effects of curcuminoid-piperine supplementation in patients with metabolic syndrome: A randomised controlled trial. Clinical Nutrition, 36(4), 1101–1108. https://doi.org/10.1016/j.clnu.2016.06.012

Pongchaidecha, A., Lailerd, N., Boonprasert, W., & Chattipakorn, N. (2012). Effects of curcuminoid supplement on cardiac autonomic status in pre-diabetic individuals. Nutrition, 28(7–8), e1–e6. https://doi.org/10.1016/j.nut.2012.01.013

Prasad, S., & Aggarwal, B. B. (2011). Turmeric, the golden spice: From traditional medicine to modern medicine. In I. F. F. Benzie & S. Wachtel-Galor (Eds.), Herbal Medicine: Biomolecular and Clinical Aspects (2nd ed., Chapter 13). CRC Press.

Prasad, S., Tyagi, A. K., & Aggarwal, B. B. (2014). Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: The golden pigment from golden spice. Cancer Research and Treatment, 46(1), 2–18. https://doi.org/10.4143/crt.2014.46.1.2

Purpura, M., Lowery, R. P., Wilson, J. M., Mannan, H., Munch, G., & Jager, R. (2017). Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects. European Journal of Nutrition, 56(1), 37–48. https://doi.org/10.1007/s00394-015-1047-4

Qin, S., Huang, L., Gong, J., Shen, S., Huang, J., Ren, H., & Hu, H. (2017). Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: A meta-analysis of randomized controlled trials. Nutrition Journal, 16(1), 68. https://doi.org/10.1186/s12937-017-0293-y

Ravindran, P. N., Babu, K. N., & Sivaraman, K. (Eds.). (2007). Turmeric: The Genus Curcuma.

CRC Press.

Reagan-Shaw, S., Nihal, M., & Ahmad, N. (2008). Dose translation from animal to human studies revisited. FASEB Journal, 22(3), 659–661. https://doi.org/10.1096/fj.07-9574LSF

Santos-Parker, J. R., Strahler, T. R., Bassett, C. J., Bispham, N. Z., Santos-Parker, M. A., & Seals,

D. R. (2017). Curcumin supplementation improves vascular endothelial function in healthy middle-aged and older adults by increasing nitric oxide bioavailability and reducing oxidative stress. Aging, 9(1), 187–208. https://doi.org/10.18632/aging.101149

Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., & Srinivas, P. S. R. K. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica, 64(4), 353–356. https://doi.org/10.1055/s-2006-957450

Stamler, J., Stamler, R., & Neaton, J. D. (1993). Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Archives of Internal Medicine, 153(5), 598–615.

Sugawara, J., Akazawa, N., Miyaki, A., Choi, Y., Tanabe, Y., Imai, T., & Maeda, S. (2012). Effect of endurance exercise training and curcumin intake on central arterial hemodynamics in postmenopausal women. American Journal of Hypertension, 25(6), 651–656. https://doi.org/10.1038/ajh.2012.24

Suresh Babu, P., & Srinivasan, K. (1997). Hypolipidemic action of curcumin, the active principle of turmeric in streptozotocin-induced diabetic rats. Molecular and Cellular Biochemistry, 166(1–2), 169–175. https://doi.org/10.1023/A:1006850027522

Tayyem, R. F., Heath, D. D., Al-Delaimy, W. K., & Rock, C. L. (2006). Curcumin content of turmeric and curry powders. Nutrition and Cancer, 55(2), 126–131. https://doi.org/10.1207/s15327914nc5502_2

Thota, R. N., Acharya, S. H., & Garg, M. L. (2019). Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes. Lipids in Health and Disease, 18(1), 31. https://doi.org/10.1186/s12944-019-0967-x

Tian, H., Guo, X., Wang, X., He, Z., Sun, R., Ge, S., & Zhang, Z. (2015). Curcumin-induced regulation of expression of angiotensin II receptors in spontaneously hypertensive rats. Pharmacology & Pharmacy, 6(2), 93–99. https://doi.org/10.4236/pp.2015.62011

Vanhoutte, P. M., Shimokawa, H., Feletou, M., & Tang, E. H. C. (2017). Endothelial dysfunction and vascular disease: A 30th anniversary update. Acta Physiologica, 219(1), 22–96. https://doi.org/10.1111/apha.12646

Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., ... & Wright, J. T. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Journal of the American College of Cardiology, 71(19), e127–e248. https://doi.org/10.1016/j.jacc.2017.11.006

World Health Organization. (2023). Hypertension. WHO fact sheet. https://www.who.int/news-room/fact-sheets/detail/hypertension

Xu, Y., Ku, B., Tie, L., Yao, H., Jiang, W., Ma, X., & Li, X. (2014). Curcumin reverses the effects of chronic stress on behaviour, the HPA axis, BDNF expression and phosphorylation of CREB. Brain Research, 1122(1), 56–64.

Yang, H., Xu, W., Zhou, Z., Liu, J., Li, X., Chen, L., Weng, J., & Yu, Z. (2019). Curcumin attenuates urinary excretion of albumin and indices of tubular damage in spontaneously hypertensive rats. Molecular and Cellular Biochemistry, 234(1), 245–252.